Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.

Clinical epidemiology·2026
Same author

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms.

Current medical research and opinion·2026
Same author

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Oncology and therapy·2026
Same author

FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA.

Advances in therapy·2026
Same author

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia.

Cancer treatment and research communications·2026

Related Experiment Video

Updated: Apr 4, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.7K

Medulloblastoma.

Nathan E Millard1, Kevin C De Braganca2

  • 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Journal of Child Neurology
|September 4, 2015
PubMed
Summary

Medulloblastoma, a common childhood brain tumor, requires multimodal treatment. Molecular subclassification offers potential for improved survival and quality of life in young patients.

Keywords:
chemotherapyembryonal tumormedulloblastomapediatric brain tumorposterior fossa mass

More Related Videos

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.9K
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.8K

Related Experiment Videos

Last Updated: Apr 4, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.7K
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.9K
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.8K

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Cancer Genomics

Background:

  • Medulloblastoma represents nearly 10% of pediatric brain tumors, primarily occurring in the posterior fossa.
  • These tumors can spread through the leptomeninges, complicating treatment and prognosis.
  • Current treatment involves surgery and radiation therapy for patients over 3 years old, with risk stratification impacting survival rates.

Purpose of the Study:

  • To review the current understanding of medulloblastoma treatment and outcomes.
  • To highlight the prognostic and therapeutic significance of recent molecular subclassification.
  • To explore the potential of integrating molecular data into future treatment protocols for improved patient care.

Main Methods:

  • Review of existing literature on medulloblastoma epidemiology, treatment strategies, and risk stratification.
  • Analysis of outcomes based on patient age, tumor characteristics, and risk categories.
  • Discussion of emerging molecular subclassification data and its implications.

Main Results:

  • Survival rates for standard-risk and high-risk medulloblastoma patients over 3 years are approximately 85% and 70%, respectively.
  • Outcomes are generally poorer for infants and children under 3, with notable exceptions.
  • Treatment is associated with significant morbidity, particularly in younger children.

Conclusions:

  • Molecular subclassification of medulloblastoma holds promise for refining prognostication and guiding therapeutic decisions.
  • Future treatment protocols incorporating molecular subgroups may enhance survival and reduce treatment-related morbidity.
  • Personalized treatment approaches based on molecular profiles are crucial for improving outcomes in pediatric medulloblastoma.